Skip to Main Content

Paper Details

SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.
Cancer
20
2021
ES, Ewing sarcoma, IRN, NIR, PARP, PARP1, PARP1/2, TMZ, advanced Ewing, alanine, alanine aminotransferase, alanine aminotransferase elevation, anorexia, colitis, irinotecan, niraparib, patients, poly(ADP-ribose), poly(ADP-ribose) polymerase, poly(adenosine diphosphate ribose), poly(adenosine diphosphate ribose) polymerase, sarcoma, temozolomide, thrombocytopenia
Author NameAffiliation
Lee J HelmanCancer and Blood Disease Institute, Children's Hospital of Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California
Lee J HelmanCancer and Blood Disease Institute, Children's Hospital of Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California
Jeremy WhelanUniversity College London Hospitals NHS Trust
Brigitte C WidemannNational Cancer Institute Center for Cancer Research
Douglas S HawkinsSeattle Children's Hospital
Sandra J StraussUniversity College London Hospitals NHS Trust
Sandra J StraussUniversity College London Cancer Institute
  • 1 - 7

Datasets

Release 1.2